Clinical Trial

Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)

Study acronym: PRISM
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, multi-center, randomized, sham-controlled, dose-escalation study evaluating ZM-02 in patients with advanced retinitis pigmentosa (RP).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-02; most recent amendment 2026-04-09.
Trial Details
NCT Number NCT07282457
Lead Sponsor Zhongmou Therapeutics
Conditions Retinitis Pigmentosa (RP)
Enrollment 21 participants
Start Date 2026-06-25
Primary Completion 2029-12-25 (estimated)
Study Completion 2031-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-04-13